Dr Reddy's Laboratories (DRREDDY IS) says Novo Nordisk's (NOVOB DC) Wegovy copycat will be priced competitively with 50-60% discounts feasible, according to reports
Newsquawk Staff ·
Dr Reddy's Laboratories (DRREDDY IS) says Novo Nordisk's (NOVOB DC) Wegovy copycat will be priced competitively with 50-60% discounts feasible, according to reports.
What it means
The announcement from Dr Reddy's regarding Novo Nordisk's Wegovy copycat suggests a significant price competition in the market for weight loss drugs. A 50-60% discount could indicate a strong push to capture market share, potentially impacting margins and pricing strategies for peers in the pharmaceutical sector. Investors should watch for potential ripple effects on the competitive landscape and the valuations of companies with similar offerings.
- Genmab (GMAB/GMAB DC) announced positive topline results from the global Phase 3 LiGeR-HN1 trial evaluating petosemtamab
- Eli Lilly’s (LLY) retatrutide delivered greater A1C reduction and more than double the weight loss of Novo Nordisk’s (NOVOB DC) Ozempic at its highest approved dose in head-to-head trial
- TPG pursues USD 5bln acquisition of UK data centre group Ark, according to FT
- Syngenta targets at least a USD 66bln valuation in Hong Kong IPO
- HP (HPQ), Asus (2357 TT) and Acer (2353 TT) are shifting some PC production from Thailand and Vietnam back to China to combat soaring component costs driven by AI-related memory and storage shortages, reports Nikkei citing sources
Related headlines
- Universal Music Group (UMG NA) discusses going private with buyout firms, according to Bloomberg1 day ago
- Japan's Sakana AI to build homegrown model to cut US and China reliance, reports Nikkei1 day ago
- Japan's Sakana AI to build homegrown model to cut US and China reliance, Nikkei reports1 day ago
- Foxconn (2317 TT) has brought online an AI factory powered by an NVIDIA (NVDA) DGX supercomputing cluster2 days ago
- US FDA has approved Novo's (NOVOB DC) once-weekly insulin treatment for paediatric patients with type 2 diabetes mellitus4 days ago
- Meta's (META) Muse AI to counter China models with subscribers, not ads, Nikkei reports4 days ago
- Toyota (TM) to recall 68k late model 2022-2024 Lexus NX vehicles in the US due to a display flaw4 days ago
- Genmab (GMAB) Phase 3 Rina data in ovarian cancer shows PFS and OS endpoints were met4 days ago
- TikTok’s US entity is reportedly exploring deals to secure multiple gigawatts of computing capacity over the coming years, according to CNBC4 days ago
- Infosys (INFY) Q2 2026 (INR): Net profit 78.2bln (exp. 79.3bln ), revenue 492.4bln (exp. 491.3bln); lowers FY27 revenue view5 days ago
- Anthropic and Hg have agreed to form an independent consultancy Co. targeting corporate clients, FT reports citing sources5 days ago
- European Commission will discuss drug pricing concerns raised by EU countries and pharmaceutical companies as they navigate US pressures, reports Politico5 days ago
- DeepSeek and Minimax get license for overseas use, reports Chinese Media5 days ago
- Infineum is exploring a USD 8bln sale, the FT reports6 days ago
- Schneider Electric (SU FP) announces a strategic collaboration with Nvidia (NVDA) and HPE (HPE) to accelerate the adoption of Physical AI across process and heavy industries6 days ago